Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Depreciation and Depletion (2016 - 2023)

Historic Depreciation and Depletion for Rocket Pharmaceuticals (RCKT) over the last 8 years, with Q3 2023 value amounting to $1.2 million.

  • Rocket Pharmaceuticals' Depreciation and Depletion rose 909.09% to $1.2 million in Q3 2023 from the same period last year, while for Sep 2023 it was $4.6 million, marking a year-over-year increase of 2639.76%. This contributed to the annual value of $426000.0 for FY2019, which is 2909.09% up from last year.
  • As of Q3 2023, Rocket Pharmaceuticals' Depreciation and Depletion stood at $1.2 million, which was up 909.09% from $1.2 million recorded in Q2 2023.
  • Rocket Pharmaceuticals' Depreciation and Depletion's 5-year high stood at $1.2 million during Q2 2023, with a 5-year trough of $100000.0 in Q2 2019.
  • Over the past 5 years, Rocket Pharmaceuticals' median Depreciation and Depletion value was $767000.0 (recorded in 2022), while the average stood at $601769.2.
  • In the last 5 years, Rocket Pharmaceuticals' Depreciation and Depletion changed by 0.0% in 2019 and then surged by 4797.91% in 2023.
  • Over the past 5 years, Rocket Pharmaceuticals' Depreciation and Depletion (Quarter) stood at $101000.0 in 2019, then dropped by 0.99% to $100000.0 in 2020, then surged by 700.0% to $800000.0 in 2021, then surged by 37.5% to $1.1 million in 2022, then rose by 9.09% to $1.2 million in 2023.
  • Its Depreciation and Depletion stands at $1.2 million for Q3 2023, versus $1.2 million for Q2 2023 and $1.1 million for Q1 2023.